Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples.

Choi RY, Levinson P, Guthrie BL, Lohman-Payne B, Bosire R, Liu AY, Hirbod T, Kiarie J, Overbaugh J, John-Stewart G, Broliden K, Farquhar C.

AIDS. 2012 Nov 13;26(17):2155-63. doi: 10.1097/QAD.0b013e328359b99b.

2.

Mucosal immunoglobulin A in HIV-exposed seronegative individuals.

Trabattoni D, Biasin M, Clerici M.

AIDS. 2012 Nov 13;26(17):2247-50. doi: 10.1097/QAD.0b013e32835848ee. No abstract available.

PMID:
23123517
3.

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.

Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, Clerici M, Broliden K.

AIDS. 2000 Sep 8;14(13):1917-20.

PMID:
10997395
4.

Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding.

Fiore JR, Laddago V, Lepera A, La Grasta L, Di Stefano M, Saracino A, Lopalco P, Pastore G, Angarano G.

New Microbiol. 2000 Jan;23(1):85-92.

PMID:
10946410
5.

HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships.

Levinson P, Choi RY, Cole AL, Hirbod T, Rhedin S, Payne B, Guthrie BL, Bosire R, Cole AM, Farquhar C, Broliden K.

PLoS One. 2012;7(2):e31996. doi: 10.1371/journal.pone.0031996. Epub 2012 Feb 28.

6.

Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women.

Bélec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, Ettiègne-Traore V, Maurice C, Becquart P, Matta M, Si-Mohamed A, Chomont N, Coulibaly IM, Wiktor SZ, Kazatchkine MD.

J Infect Dis. 2001 Dec 1;184(11):1412-22. Epub 2001 Nov 13.

PMID:
11709783
7.

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2016 Oct 14;90(21):9855-9861. Print 2016 Nov 1. Erratum in: J Virol. 2017 Jan 18;91(3):.

8.

Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Côte d'Ivoire.

Ghys PD, Bélec L, Diallo MO, Ettiègne-Traoré V, Becquart P, Maurice C, Nkengasong JN, Coulibaly IM, Greenberg AE, Laga M, Wiktor SZ.

AIDS. 2000 Nov 10;14(16):2603-8.

PMID:
11101074
9.

Cervicovaginal anti-HIV antibodies in index women from HIV-discordant, exclusively heterosexual, couples.

Bélec L, Prazuck T, Payan C, Mohamed AS, Cancre N, Hocini H, Malkin JE, Pillot J.

Viral Immunol. 1996;9(3):155-8.

PMID:
8890473
10.

HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein.

Carrillo J, Restrepo C, Rallón NI, Massanella M, del Romero J, Rodríguez C, Soriano V, Clotet B, Benito JM, Blanco J.

AIDS. 2013 Jun 1;27(9):1375-85. doi: 10.1097/QAD.0b013e32835fac08.

PMID:
23945502
11.

HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men.

Buchacz K, Parekh BS, Padian NS, van der Straten A, Phillips S, Jonte J, Holmberg SD.

AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1689-93.

PMID:
11788020
12.

Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.

Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barass C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K.

J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):413-20.

PMID:
12138348
13.

Non-Cationic Proteins Are Associated with HIV Neutralizing Activity in Genital Secretions of Female Sex Workers.

Birse KD, Cole AL, Hirbod T, McKinnon L, Ball TB, Westmacott GR, Kimani J, Plummer F, Cole AM, Burgener A, Broliden K.

PLoS One. 2015 Jun 19;10(6):e0130404. doi: 10.1371/journal.pone.0130404. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134196.

14.

Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Mbopi-Kéou FX, Bélec L, Dalessio J, Legoff J, Grésenguet G, Mayaud P, Brown DW, Morrow RA.

Clin Diagn Lab Immunol. 2003 May;10(3):388-93.

15.

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers.

Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA.

AIDS. 1999 Jan 14;13(1):23-9.

PMID:
10207541
16.

Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC, Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M.

AIDS Res Hum Retroviruses. 2011 May;27(5):469-86. doi: 10.1089/aid.2010.0169. Epub 2010 Nov 22.

17.

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.

Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, Reynes JM, Lopalco L, Bomsel M.

Mucosal Immunol. 2009 Sep;2(5):412-26. doi: 10.1038/mi.2009.89. Epub 2009 Jul 8.

PMID:
19587640
18.

HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men.

Hirbod T, Kong X, Kigozi G, Ndyanabo A, Serwadda D, Prodger JL, Tobian AA, Nalugoda F, Wawer MJ, Shahabi K, Rojas OL, Gommerman JL, Broliden K, Kaul R, Gray RH.

PLoS Pathog. 2014 Oct 2;10(10):e1004416. doi: 10.1371/journal.ppat.1004416. eCollection 2014 Oct. Erratum in: PLoS Pathog. 2014 Oct;10(10):e1004515.

19.

Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Bélec L, Tévi-Bénissan C, Dupré T, Mohamed AS, Prazuck T, Gilquin J, Kanga JM, Pillot J.

J Clin Immunol. 1996 Jan;16(1):12-20.

PMID:
8926281

Supplemental Content

Support Center